M&A Deal Summary

Cubist Pharmaceuticals Acquires Illumigen Biosciences

On December 26, 2007, Cubist Pharmaceuticals acquired life science company Illumigen Biosciences

Acquisition Highlights
  • This is Cubist Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Cubist Pharmaceuticals’ 1st transaction in the United States.
  • This is Cubist Pharmaceuticals’ 1st transaction in Washington.

M&A Deal Summary
Date 2007-12-26
Target Illumigen Biosciences
Sector Life Science
Buyer(s) Cubist Pharmaceuticals
Deal Type Add-on Acquisition

Target

Illumigen Biosciences

Seattle, Washington, United States
Illumigen Biosciences, Inc. discovers beneficial human genetic mutations that might provide a roadmap for novel therapeutic drug mechanisms.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cubist Pharmaceuticals

Lexington, Massachusetts, United States
Category Company
Founded 1992
Sector Life Science
Employees900
Revenue 1.1B USD (2013)
DESCRIPTION

Cubist Pharmaceuticals, Inc. is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

DEAL STATS #
Overall 1 of 5
Sector (Life Science) 1 of 5
Type (Add-on Acquisition) 1 of 5
State (Washington) 1 of 1
Country (United States) 1 of 5
Year (2007) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-12-14 Calixa Therapeutics

San Diego, California, United States

Calixa Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

Buy -
Mergr

Product

Company

Legal